Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2012

01.01.2012 | Preclinical study

Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint

verfasst von: Melanie M. Badtke, Purevsuren Jambal, Wendy W. Dye, Monique A. Spillman, Miriam D. Post, Kathryn B. Horwitz, Britta M. Jacobsen

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Whether the presence of steroid receptors in luminal breast cancers renders them resistant to taxanes remains uncertain. Here we assess the role of progesterone receptors (PR) on taxane-induced cell death. We previously showed that estrogen receptor (ER)-positive human breast cancer cells that inducibly express PR-A or PR-B isoforms were protected from taxane-stimulated apoptosis when compared to the identical cells lacking PR. Surprisingly, PR-dependent protection occurred in the absence of progesterone, demonstrating that the unliganded receptors were biologically active. The present studies demonstrate that unliganded PR, focused on PR-A, protect breast cancer cells from taxane-stimulated apoptosis. The studies identify genes regulated by taxanes in isogenic ER-positive cells that either lack or express PR-A. We show that unliganded PR-A alters the gene expression pattern controlled by taxanes, especially multiple genes involved in the spindle assembly checkpoint, a group of proteins that insure proper attachment of microtubules to kinetochores during mitosis. Importantly, taxanes and unliganded PR regulate many of these genes in opposite directions. As a result, mitotic slippage is exacerbated by the presence of PR, leading to an increase in the number of multinucleated cells both in vitro and in xenograft tumors. We describe a simple new assay for assessing multinucleation in paraffin sections. We speculate that rather than inducing cell death, unliganded PR exploits multinucleation to promote cell survival from taxane therapy. This can be prevented with antiprogestin.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13(12):2879–2885PubMed Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13(12):2879–2885PubMed
2.
Zurück zum Zitat Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16(10):3362–3368PubMed Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16(10):3362–3368PubMed
3.
Zurück zum Zitat Sawaki M, Ito Y, Hashimoto D, Mizunuma N, Takahashi S, Horikoshi N, Tada K, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A, Hatake K (2004) Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori 90(1):36–39PubMed Sawaki M, Ito Y, Hashimoto D, Mizunuma N, Takahashi S, Horikoshi N, Tada K, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A, Hatake K (2004) Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori 90(1):36–39PubMed
5.
Zurück zum Zitat Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM (2006) cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 96(1):17–39PubMedCrossRef Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM (2006) cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 96(1):17–39PubMedCrossRef
6.
Zurück zum Zitat Chen JG, Yang CP, Cammer M, Horwitz SB (2003) Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 63(22):7891–7899PubMed Chen JG, Yang CP, Cammer M, Horwitz SB (2003) Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 63(22):7891–7899PubMed
7.
8.
Zurück zum Zitat Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820–13825. doi:10.1073/pnas.0905718106 PubMedCrossRef Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820–13825. doi:10.​1073/​pnas.​0905718106 PubMedCrossRef
9.
Zurück zum Zitat Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB (2006) Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 66(18):9308–9315PubMedCrossRef Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB (2006) Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 66(18):9308–9315PubMedCrossRef
11.
Zurück zum Zitat Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983PubMedCrossRef Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983PubMedCrossRef
12.
Zurück zum Zitat Sui M, Huang Y, Park BH, Davidson NE, Fan W (2007) Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 67(11):5337–5344PubMedCrossRef Sui M, Huang Y, Park BH, Davidson NE, Fan W (2007) Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 67(11):5337–5344PubMedCrossRef
13.
Zurück zum Zitat Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D (2004) Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 3(5):460–467PubMed Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D (2004) Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 3(5):460–467PubMed
14.
Zurück zum Zitat Schmidt M, Bremer E, Hasenclever D, Victor A, Gehrmann M, Steiner E, Schiffer IB, Gebhardt S, Lehr HA, Mahlke M, Hermes M, Mustea A, Tanner B, Koelbl H, Pilch H, Hengstler JG (2007) Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br J Cancer 96(2):241–247PubMedCrossRef Schmidt M, Bremer E, Hasenclever D, Victor A, Gehrmann M, Steiner E, Schiffer IB, Gebhardt S, Lehr HA, Mahlke M, Hermes M, Mustea A, Tanner B, Koelbl H, Pilch H, Hengstler JG (2007) Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br J Cancer 96(2):241–247PubMedCrossRef
15.
Zurück zum Zitat Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676PubMedCrossRef Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676PubMedCrossRef
16.
Zurück zum Zitat Jacobsen BM, Schittone SA, Richer JK, Horwitz KB (2005) Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19(3):574–587PubMedCrossRef Jacobsen BM, Schittone SA, Richer JK, Horwitz KB (2005) Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19(3):574–587PubMedCrossRef
17.
Zurück zum Zitat Jacobsen BM, Richer JK, Schittone SA, Horwitz KB (2002) New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem 277(31):27793–27800PubMedCrossRef Jacobsen BM, Richer JK, Schittone SA, Horwitz KB (2002) New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem 277(31):27793–27800PubMedCrossRef
18.
Zurück zum Zitat Ghatge RP, Jacobsen BM, Schittone SA, Horwitz KB (2005) The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res 7(6):R1036–R1050. doi:10.1186/bcr1340 PubMedCrossRef Ghatge RP, Jacobsen BM, Schittone SA, Horwitz KB (2005) The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res 7(6):R1036–R1050. doi:10.​1186/​bcr1340 PubMedCrossRef
23.
Zurück zum Zitat Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, Jaulin C (2007) Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res 67(13):6360–6367. doi:10.1158/0008-5472.CAN-06-3012 PubMedCrossRef Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, Jaulin C (2007) Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res 67(13):6360–6367. doi:10.​1158/​0008-5472.​CAN-06-3012 PubMedCrossRef
24.
Zurück zum Zitat Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O’Connell P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362(9381):362–369PubMedCrossRef Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O’Connell P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362(9381):362–369PubMedCrossRef
25.
Zurück zum Zitat Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23(3):422–431. doi:10.1200/JCO.2005.09.078 PubMedCrossRef Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23(3):422–431. doi:10.​1200/​JCO.​2005.​09.​078 PubMedCrossRef
26.
Zurück zum Zitat Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M, Hasegawa T, Hirata K, Nakamura Y (2009) Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol 34(2):361–370PubMed Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M, Hasegawa T, Hirata K, Nakamura Y (2009) Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol 34(2):361–370PubMed
27.
Zurück zum Zitat Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23(29):7265–7277PubMedCrossRef Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23(29):7265–7277PubMedCrossRef
30.
Zurück zum Zitat Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR, Desai R, Schauer SP, McNulty DE, Annan RS, Belmont LD, Garcia C, Lee Y, Diamond MA, Faucette LF, Giardiniere M, Zhang S, Sun CM, Vidal JD, Lichtsteiner S, Cornwell WD, Greshock JD, Wooster RF, Finer JT, Copeland RA, Huang PS, Morgans DJ Jr, Dhanak D, Bergnes G, Sakowicz R, Jackson JR (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA 107(13):5839–5844. doi:10.1073/pnas.0915068107 PubMedCrossRef Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR, Desai R, Schauer SP, McNulty DE, Annan RS, Belmont LD, Garcia C, Lee Y, Diamond MA, Faucette LF, Giardiniere M, Zhang S, Sun CM, Vidal JD, Lichtsteiner S, Cornwell WD, Greshock JD, Wooster RF, Finer JT, Copeland RA, Huang PS, Morgans DJ Jr, Dhanak D, Bergnes G, Sakowicz R, Jackson JR (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA 107(13):5839–5844. doi:10.​1073/​pnas.​0915068107 PubMedCrossRef
32.
Zurück zum Zitat Sasai K, Parant JM, Brandt ME, Carter J, Adams HP, Stass SA, Killary AM, Katayama H, Sen S (2008) Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene 27(29):4122–4127. doi:10.1038/onc.2008.47 PubMedCrossRef Sasai K, Parant JM, Brandt ME, Carter J, Adams HP, Stass SA, Killary AM, Katayama H, Sen S (2008) Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene 27(29):4122–4127. doi:10.​1038/​onc.​2008.​47 PubMedCrossRef
33.
Zurück zum Zitat Schliekelman M, Cowley DO, O’Quinn R, Oliver TG, Lu L, Salmon ED, Van Dyke T (2009) Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res 69(1):45–54. doi:10.1158/0008-5472.CAN-07-6330 PubMedCrossRef Schliekelman M, Cowley DO, O’Quinn R, Oliver TG, Lu L, Salmon ED, Van Dyke T (2009) Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res 69(1):45–54. doi:10.​1158/​0008-5472.​CAN-07-6330 PubMedCrossRef
34.
Zurück zum Zitat Putkey FR, Cramer T, Morphew MK, Silk AD, Johnson RS, McIntosh JR, Cleveland DW (2002) Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 3(3):351–365. doi:S1534580702002551[pii] PubMedCrossRef Putkey FR, Cramer T, Morphew MK, Silk AD, Johnson RS, McIntosh JR, Cleveland DW (2002) Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 3(3):351–365. doi:S153458070200255​1[pii] PubMedCrossRef
35.
Zurück zum Zitat Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, Dobles M, Sorger PK, Murty VV, Benezra R (2001) MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409(6818):355–359. doi:10.1038/35053094 PubMedCrossRef Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, Dobles M, Sorger PK, Murty VV, Benezra R (2001) MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409(6818):355–359. doi:10.​1038/​35053094 PubMedCrossRef
36.
Zurück zum Zitat Musio A, Montagna C, Zambroni D, Indino E, Barbieri O, Citti L, Villa A, Ried T, Vezzoni P (2003) Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. Cancer Res 63(11):2855–2863PubMed Musio A, Montagna C, Zambroni D, Indino E, Barbieri O, Citti L, Villa A, Ried T, Vezzoni P (2003) Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. Cancer Res 63(11):2855–2863PubMed
37.
Zurück zum Zitat Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392(6673):300–303. doi:10.1038/32688 PubMedCrossRef Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392(6673):300–303. doi:10.​1038/​32688 PubMedCrossRef
38.
Zurück zum Zitat Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R (2004) Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci USA 101(13):4459–4464. doi:10.1073/pnas.0306069101 PubMedCrossRef Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R (2004) Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci USA 101(13):4459–4464. doi:10.​1073/​pnas.​0306069101 PubMedCrossRef
39.
Zurück zum Zitat Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12(2):405–410. doi:10.1158/1078-0432.CCR-05-0903 PubMedCrossRef Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12(2):405–410. doi:10.​1158/​1078-0432.​CCR-05-0903 PubMedCrossRef
41.
Zurück zum Zitat Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3(1):51–62.PubMedCrossRef Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3(1):51–62.PubMedCrossRef
42.
Zurück zum Zitat Wysong DR, Chakravarty A, Hoar K, Ecsedy JA (2009) The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 8(6):876–888.PubMedCrossRef Wysong DR, Chakravarty A, Hoar K, Ecsedy JA (2009) The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 8(6):876–888.PubMedCrossRef
43.
Zurück zum Zitat Merlin JL, Bour-Dill C, Marchal S, Bastien L, Gramain MP (2000) Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells. Anticancer Drugs 11(4):295–302PubMedCrossRef Merlin JL, Bour-Dill C, Marchal S, Bastien L, Gramain MP (2000) Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells. Anticancer Drugs 11(4):295–302PubMedCrossRef
44.
Zurück zum Zitat Panvichian R, Orth K, Day ML, Day KC, Pilat MJ, Pienta KJ (1998) Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 58(20):4667–4672PubMed Panvichian R, Orth K, Day ML, Day KC, Pilat MJ, Pienta KJ (1998) Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 58(20):4667–4672PubMed
45.
Zurück zum Zitat Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W (2002) Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59(7):1198–1211PubMedCrossRef Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W (2002) Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59(7):1198–1211PubMedCrossRef
46.
Zurück zum Zitat Roberts JR, Allison DC, Donehower RC, Rowinsky EK (1990) Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 50(3):710–716PubMed Roberts JR, Allison DC, Donehower RC, Rowinsky EK (1990) Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 50(3):710–716PubMed
48.
Zurück zum Zitat Erenpreisa J, Ivanov A, Wheatley SP, Kosmacek EA, Ianzini F, Anisimov AP, Mackey M, Davis PJ, Plakhins G, Illidge TM (2008) Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase. Cell Biol Int 32(9):1044–1056. doi:10.1016/j.cellbi.2008.06.003 PubMedCrossRef Erenpreisa J, Ivanov A, Wheatley SP, Kosmacek EA, Ianzini F, Anisimov AP, Mackey M, Davis PJ, Plakhins G, Illidge TM (2008) Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase. Cell Biol Int 32(9):1044–1056. doi:10.​1016/​j.​cellbi.​2008.​06.​003 PubMedCrossRef
49.
Zurück zum Zitat Ivanov A, Cragg MS, Erenpreisa J, Emzinsh D, Lukman H, Illidge TM (2003) Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci 116(Pt 20):4095–4106. doi:10.1242/jcs.00740 PubMedCrossRef Ivanov A, Cragg MS, Erenpreisa J, Emzinsh D, Lukman H, Illidge TM (2003) Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci 116(Pt 20):4095–4106. doi:10.​1242/​jcs.​00740 PubMedCrossRef
51.
Zurück zum Zitat Classen S, Possinger K, Pelka-Fleischer R, Wilmanns W (1993) Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol 45(4):315–319PubMedCrossRef Classen S, Possinger K, Pelka-Fleischer R, Wilmanns W (1993) Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol 45(4):315–319PubMedCrossRef
52.
Zurück zum Zitat Hackenberg R, Hannig K, Beck S, Schmidt-Rhode P, Scholz A, Schulz KD (1996) Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells. Eur J Cancer 32A(4):696–701PubMedCrossRef Hackenberg R, Hannig K, Beck S, Schmidt-Rhode P, Scholz A, Schulz KD (1996) Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells. Eur J Cancer 32A(4):696–701PubMedCrossRef
53.
Zurück zum Zitat Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H (1987) The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 74(4):455–461PubMed Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H (1987) The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 74(4):455–461PubMed
54.
Zurück zum Zitat Maibauer RZC, Schultz-Mosgau M, Rohde B, Kuss I, Sittner W, Scherling AG (2006) Abstract #4074: First human data for ZK 230211 (ZK-PRA), a new progesterone receptor antagonist: a phase I clinical analysis of safety and pharmakokinetics in healthy postmenopausal women. Breast Cancer Res Treat 100(Supplement 1):S196 Maibauer RZC, Schultz-Mosgau M, Rohde B, Kuss I, Sittner W, Scherling AG (2006) Abstract #4074: First human data for ZK 230211 (ZK-PRA), a new progesterone receptor antagonist: a phase I clinical analysis of safety and pharmakokinetics in healthy postmenopausal women. Breast Cancer Res Treat 100(Supplement 1):S196
55.
Zurück zum Zitat Erenpreisa J, Cragg MS (2001) Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1(1):1PubMedCrossRef Erenpreisa J, Cragg MS (2001) Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1(1):1PubMedCrossRef
Metadaten
Titel
Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint
verfasst von
Melanie M. Badtke
Purevsuren Jambal
Wendy W. Dye
Monique A. Spillman
Miriam D. Post
Kathryn B. Horwitz
Britta M. Jacobsen
Publikationsdatum
01.01.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1399-0

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research and Treatment 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.